1. Executive Summary

• 1.1 Market Overview and Definition

• 1.2 Key Market Highlights and Findings

• 1.3 Market Size and Growth Projections (Base Year: 2025 | Current Year: 2026 | Forecast: 2026–2033)

• 1.4 Market Segmentation Snapshot

• 1.5 Regional Market Snapshot

• 1.6 Competitive Landscape Overview

• 1.7 Key Growth Drivers and Strategic Insights

2. Research Methodology

• 2.1 Research Framework and Approach

• 2.2 Data Collection Methods

  • 2.2.1 Primary Research (Biodefense Scientists, Public Health Officials, Military Medical Officers, Veterinarians, Animal Health Specialists, Vaccine R&D Directors, Biodefense Procurement Officers, BARDA/NIH Program Managers, C-Suite Consultation)

  • 2.2.2 Secondary Research (CDC Anthrax Surveillance Reports, WHO Global Zoonotic Disease Data, USDA APHIS Anthrax Surveillance, BARDA Biodefense Procurement Contracts, Vaccine Journal Publications, FDA CBER Regulatory Filings, Company Annual Reports, Patent Databases, Clinical Trial Registries)

• 2.3 Market Size Estimation Methodology

  • 2.3.1 Top-Down Approach

  • 2.3.2 Bottom-Up Approach

• 2.4 Data Triangulation and Validation Process

• 2.5 Forecasting Models and Techniques

• 2.6 Research Assumptions and Limitations

• 2.7 Base Year (2025), Current Year (2026), and Forecast Period (2026–2033)

3. Market Introduction

• 3.1 Market Definition and Scope

• 3.2 Overview of Anthrax and Bacillus anthracis: Disease Biology, Spore Formation, Cutaneous/Inhalation/Gastrointestinal/Injection Anthrax Forms, Zoonotic Transmission Routes, and Global Outbreak History

• 3.3 Classification of Anthrax Vaccines: Cell-Free Protective Antigen (PA) Vaccines (Anthrax Vaccine Adsorbed/AVA, Anthrax Vaccine Precipitated/AVP), Live Attenuated Vaccines (Sterne Strain), Recombinant Subunit Vaccines, and Next-Generation Anthrax Vaccine Platforms

• 3.4 Dual-Use Nature of the Anthrax Vaccine Market: Biodefense and Military Human Vaccination Programs vs. Veterinary/Livestock Anthrax Control Programs

• 3.5 Evolution of Anthrax Vaccines: From Greenfield Live Attenuated Vaccines (Sterne Strain – 1937) and UK/U.S. AVP/AVA Licensed Products to Recombinant PA Vaccines (rPA102, AV7909), Next-Generation Adjuvanted Platforms, and Anthrax Monoclonal Antibodies (Obiltoxaximab/Anthim, Raxibacumab/ABthrax)

• 3.6 Strategic Role of Anthrax Vaccines: U.S. Strategic National Stockpile (SNS) Biodefense Procurement, NATO Military Pre-Exposure Prophylaxis Programs, Occupational Risk Group Vaccination (Laboratory Workers, Veterinarians, Agricultural Workers), and Livestock Vaccination Programs in Africa and Asia

• 3.7 Anthrax as a Bioterrorism Agent: CDC Category A Select Agent Classification, U.S. Biodefense Policy (Project BioShield Act, BARDA, PHEMCE), and International Biodefense Vaccine Stockpiling Programs

• 3.8 Market Taxonomy and Segmentation Framework

• 3.9 Currency and Units Considered

• 3.10 Stakeholder Ecosystem

4. Anthrax Vaccine Market Characteristics

• 4.1 Vaccine Type Overview (Cell-Free Protective Antigen/PA Vaccines – AVA/BioThrax and AVP/Anthrax Vaccine Precipitated; Live Attenuated Vaccines – Sterne Strain; Recombinant Subunit Vaccines – rPA102, AV7909; Next-Generation Platform Vaccines)

• 4.2 Vaccine Platform Overview (Cell-Free PA Vaccine Platform, Live Attenuated Bacillus anthracis Sterne Strain, Recombinant Protective Antigen/rPA Vaccines, DNA Vaccines, Viral Vector-Based Vaccines, Nanoparticle-Based Anthrax Vaccines)

• 4.3 Application Overview (Human Use – Biodefense/Military and Occupational; Animal Use – Livestock and Wildlife Vaccination)

• 4.4 Route of Administration Overview (Subcutaneous/Intramuscular Injection, Transdermal, Intranasal/Mucosal – Pipeline)

• 4.5 End-User Overview (Military and Defense Agencies, Government Biodefense Stockpile Programs, Hospitals and Clinics, Veterinary Hospitals and Clinics, Research and Academic Institutes, Agricultural and Livestock Organizations)

• 4.6 Distribution Channel Overview (Government Biodefense Procurement/BARDA/SNS, Hospital Pharmacies, Veterinary Distributors, Specialty Distributors, Online Medical Supply)

• 4.7 Regulatory Classification: FDA BLA for Human Anthrax Vaccines (BioThrax BLA#103821), USDA Veterinary Biologics License for Animal Anthrax Vaccines, EMA Conditional Marketing Authorization for Anthrax Countermeasures, and BARDA PHEMCE Procurement Contracts

• 4.8 Comparison: AVA/BioThrax (Cell-Free PA Adsorbed) vs. AVP (Cell-Free PA Precipitated) vs. Live Attenuated Sterne Strain vs. Recombinant rPA102/AV7909 – Efficacy, Safety Profile, Dosing Schedule, Storage Requirements, and Regulatory Status

5. Assumptions and Acronyms Used

• 5.1 List of Key Assumptions

• 5.2 Currency and Pricing Considerations

• 5.3 Acronyms and Abbreviations

6. Market Dynamics

• 6.1 Introduction

• 6.2 Market Drivers

  • 6.2.1 Rising Government Biodefense Investment and Strategic National Stockpile (SNS) Procurement: BARDA Multi-Year BioThrax/AV7909 Contracts and NATO Military Anthrax Vaccination Program Expansion

  • 6.2.2 Growing Bioterrorism Threat Awareness: Anthrax as CDC Category A Bioterrorism Agent; Post-2001 Anthrax Letter Attack Legacy Driving Sustained U.S. and Allied Nation Biodefense Preparedness Investment

  • 6.2.3 Rising Veterinary Anthrax Vaccine Demand: High Livestock Population in Africa, Asia, and Latin America; Recurring Anthrax Outbreaks in Cattle, Sheep, Goats, and Wildlife (Kazakhstan, Siberia, Zimbabwe, Uganda)

  • 6.2.4 Expanding Occupational Risk Group Vaccination Programs: Laboratory Workers, Veterinarians, Agricultural Workers, Wildlife Conservationists, and Wool/Textile Industry Workers in Anthrax-Endemic Regions

  • 6.2.5 Next-Generation Vaccine Development: Recombinant PA Vaccines (AV7909/rPA+CPG7909) Offering Reduced Dosing Schedule and Improved Immunogenicity; Thermostable Formulations for LMIC Field Deployment

  • 6.2.6 Climate Change-Driven Anthrax Outbreak Risk: Permafrost Thawing (Siberia 2016 Reindeer Anthrax Outbreak) and Changing Environmental Conditions Releasing Dormant Anthrax Spores, Driving Surveillance and Vaccination Preparedness Investment

  • 6.2.7 Asia-Pacific Fastest-Growing Regional Market: Rising Government Attention to Infectious Disease Prevention, Large Livestock Populations, and Growing Zoonotic Disease Control Investment in India, China, and Southeast Asia

• 6.3 Market Restraints

  • 6.3.1 Complex and Lengthy Multi-Dose Vaccination Schedule for BioThrax (AVA): 5-Dose Priming Series + Annual Boosters Creating Compliance Challenges in Both Military and Civilian Programs

  • 6.3.2 Adverse Injection Site Reactions and Local Reactogenicity of Current Cell-Free PA Vaccines Limiting Broad Civilian Population Vaccination Programs

  • 6.3.3 Highly Concentrated Government Procurement: Dependence on BARDA/SNS Contracts Creating Commercial Revenue Concentration Risk for Anthrax Vaccine Manufacturers

  • 6.3.4 Cold Chain and Storage Requirements Limiting Deployment of Current Anthrax Vaccines in Remote and Resource-Limited Endemic Regions in Africa and Asia

• 6.4 Market Opportunities

  • 6.4.1 AV7909 (Anthrax Vaccine Adsorbed + CPG 7909 Adjuvant) Post-Exposure Prophylaxis Approval Pathway: Emergency Use Authorization (EUA) and Potential FDA Full BLA for Inhalation Anthrax Post-Exposure Prophylaxis

  • 6.4.2 Recombinant Anthrax Vaccine Platform Innovation: GC Biopharma Recombinant rPA Vaccine, iBio AI-Guided Antibody Design, and Thermostable Lyophilized Anthrax Vaccine Formulations for Global South Deployment

  • 6.4.3 Expansion of Anthrax Monoclonal Antibody Countermeasures: Obiltoxaximab (Anthim) and Raxibacumab (ABthrax) as Complement Therapies for SNS Stockpiling and Post-Exposure Prophylaxis Programs

  • 6.4.4 Veterinary Anthrax Vaccine Market Expansion in Asia-Pacific and Sub-Saharan Africa: WOAH/OIE-Supported Livestock Vaccination Programs and Government-Funded Agricultural Health Programs

  • 6.4.5 One Health Approach Integration: Combined Human and Animal Anthrax Surveillance and Vaccination Programs at the Human-Animal-Environment Interface

• 6.5 Market Challenges

  • 6.5.1 Animal Efficacy Rule Challenge: FDA Animal Rule-Based Approval Pathway for Anthrax Vaccines Creating Regulatory Complexity and Extended Development Timelines

  • 6.5.2 Limited Commercial Market Beyond Biodefense Contracts: Small Occupational and Civilian Vaccination Population Restricting Non-Government Revenue Potential

  • 6.5.3 Competitive Threat from Alternative Biodefense Countermeasures: Anthrax Antitoxin Monoclonal Antibodies and Ciprofloxacin/Doxycycline Post-Exposure Antibiotic Prophylaxis Reducing Exclusive Reliance on Anthrax Vaccination

  • 6.5.4 Global Veterinary Anthrax Vaccine Market Fragmentation: Diverse Sterne Strain Product Sources, USDA/WOAH Regulatory Heterogeneity, and Variable Quality Standards Across LMIC Veterinary Vaccine Manufacturers

• 6.6 Market Trends

  • 6.6.1 Cell-Free Protective Antigen (PA) Vaccine Segment Dominating (~63.40% Share in 2025)​

  • 6.6.2 Recombinant Subunit Vaccines (AV7909, rPA102, GC Biopharma rPA) Fastest-Growing Vaccine Type

  • 6.6.3 Animal Use Segment Dominating Application (~Largest Share in 2025); Human Use Fastest-Growing Application Driven by Biodefense Investment

  • 6.6.4 Military and Defense End-User Dominating Human Anthrax Vaccine Segment; Veterinary Hospitals and Clinics Dominating Animal Use Segment

  • 6.6.5 North America Dominating Regional Market (~44.70% Share in 2025); Asia-Pacific Fastest-Growing Region

  • 6.6.6 Government Biodefense Procurement (BARDA/SNS) Dominating Distribution Channel

7. Value Chain and Ecosystem Analysis

• 7.1 Overview of Anthrax Vaccine Market Value Chain

• 7.2 Upstream: Bacillus anthracis Sterne Strain Culture, Protective Antigen (PA) Protein Extraction and Purification, Recombinant PA Expression System Development, and Adjuvant (Alhydrogel, CPG7909) Sourcing

• 7.3 Vaccine Manufacturing: BSL-2/BSL-3 GMP Biologics Manufacturing, Sterile Filling, Lyophilization, Quality Control Batch Release Testing, and Thermostable Formulation Development

• 7.4 Contract Manufacturing and CDMO Partnerships: Scorpius BioManufacturing–Anthim (Obiltoxaximab) Arrangement, EMERGENT BioSolutions BioThrax Manufacturing, and GC Biopharma Recombinant rPA Production

• 7.5 Regulatory Approval and BARDA Procurement: FDA BLA/EUA Pathway (Animal Rule), BARDA Contract Award, PHEMCE Allocation, and SNS Stockpile Management

• 7.6 Distribution: BARDA/SNS Government Procurement, Military Direct Supply, Veterinary Distributor Networks (Africa, Asia, Latin America), Hospital Pharmacy, and Specialty Distributor Channels

• 7.7 End Users: Military and Defense Agencies, Government Biodefense Stockpile Programs, Hospitals and Clinics, Veterinary Hospitals and Clinics, Agricultural Organizations, Research Institutes

• 7.8 Regulatory and Public Health Ecosystem (FDA CBER, BARDA, SNS, USDA APHIS, WOAH/OIE, EMA, NIH/NIAID, CDC, PHEMCE, NATO Allied Medical Publication)

• 7.9 Value Addition at Each Stage

8. Porter's Five Forces Analysis

• 8.1 Threat of New Entrants

• 8.2 Bargaining Power of Suppliers (PA Protein Antigen Suppliers, Adjuvant Manufacturers – Alhydrogel/CPG7909, BSL-3 CDMO Manufacturers, Lyophilization Specialists, Cold Chain Logistics Providers)

• 8.3 Bargaining Power of Buyers (BARDA/U.S. Government – Dominant Buyer for Human Vaccines, NATO Military Medical Commands, National Ministries of Agriculture for Veterinary Vaccines, WOAH-Supported National Veterinary Programs)

• 8.4 Threat of Substitutes (Anthrax Antitoxin mAbs – Obiltoxaximab/Anthim and Raxibacumab/ABthrax for Post-Exposure; Antibiotic Post-Exposure Prophylaxis – Ciprofloxacin, Doxycycline; Passive Immunotherapy with Anthrax Antitoxin)

• 8.5 Intensity of Competitive Rivalry

9. PESTEL Analysis

• 9.1 Political Factors (Project BioShield Act, BARDA Biodefense Funding, U.S. PHEMCE Strategy, NATO Biodefense Policy, USDA APHIS Veterinary Biologics Regulation, WOAH International Animal Health Standards for Anthrax Control)

• 9.2 Economic Factors (BARDA Long-Term Procurement Contracts as Primary Market Revenue Driver, SNS Budget Allocation for Anthrax Vaccine Stockpiling, Economic Cost of Livestock Anthrax Outbreaks in Developing Economies, CDMO Partnership Economics)

• 9.3 Social Factors (Bioterrorism Threat Awareness Since 2001 Anthrax Letter Attacks, Climate Change-Driven Anthrax Spore Release from Permafrost, Public Perception of Anthrax Vaccination Safety, One Health Approach Gaining Acceptance)

• 9.4 Technological Factors (Recombinant Protein Antigen Vaccine Platforms, CPG7909 TLR9 Agonist Adjuvant Technology, Thermostable Lyophilized Formulations, Synthetic Biology for PA Antigen Production, AI-Guided Antibody Design, Nanoparticle Anthrax Vaccine Delivery, IL-33 Adjuvant Systems)

• 9.5 Environmental Factors (Climate Change and Permafrost Thaw as Emerging Anthrax Outbreak Risk Factor, Anthrax Spore Persistence in Soil and Environmental Decontamination Challenge, One Health Surveillance at Human-Animal-Environment Interface, BSL-3 Facility Environmental Safety)

• 9.6 Legal and Regulatory Factors (FDA Animal Rule for Anthrax Vaccine Efficacy Studies in Non-Human Primates and Rabbits, FDA BLA and EUA Pathways for CBRN Medical Countermeasures, BARDA Other Transaction Authority (OTA) Contracts, USDA Veterinary Biologics Licensing, International Export Controls on Anthrax Vaccine-Related Biological Materials)

10. Market Attractiveness Analysis

• 10.1 By Vaccine Type (Cell-Free PA Vaccines – AVA/BioThrax and AVP; Live Attenuated Sterne Strain; Recombinant Subunit Vaccines – AV7909/rPA102; Next-Generation Platforms)

• 10.2 By Vaccine Platform (Cell-Free PA, Live Attenuated, Recombinant rPA, DNA Vaccine, Viral Vector, Nanoparticle-Based)

• 10.3 By Application (Human Use – Biodefense/Military and Occupational; Animal Use – Livestock and Wildlife)

• 10.4 By Route of Administration (Subcutaneous/Intramuscular Injection, Transdermal, Intranasal/Mucosal)

• 10.5 By End User (Military and Defense Agencies, Government Biodefense Stockpile Programs, Hospitals and Clinics, Veterinary Hospitals and Clinics, Research and Academic Institutes, Agricultural and Livestock Organizations)

• 10.6 By Distribution Channel (Government Biodefense Procurement/BARDA/SNS, Hospital Pharmacies, Veterinary Distributors, Specialty Distributors, Online Medical Supply)

• 10.7 By Region

11. COVID-19 Impact Analysis

• 11.1 Pandemic-Driven Reallocation of Biodefense Research and Procurement Resources: Short-Term Delay in Anthrax Vaccine Development Programs and BARDA Contract Reviews During COVID-19

• 11.2 mRNA Vaccine Technology Acceleration During COVID-19: Potential Application of mRNA Platform to Next-Generation Anthrax Vaccine Development

• 11.3 COVID-19 Strengthening Biodefense Preparedness Awareness: Post-Pandemic Renewed Government Focus on CBRN Medical Countermeasure Stockpiling and Pandemic/Bioterrorism Dual-Use Preparedness

• 11.4 Supply Chain Resilience Investments Post-COVID-19: BARDA and Defense Industrial Base Investment in Domestic Anthrax Vaccine Manufacturing Capacity and Supply Chain Redundancy

12. Anthrax Vaccine Technology and Innovation Landscape

• 12.1 Current Licensed Human Anthrax Vaccines: BioThrax (AVA/Anthrax Vaccine Adsorbed – Emergent BioSolutions, FDA BLA Licensed) and CHPA AVP (Porton Biopharma, UK) – Regulatory Status, Dosing Schedules, and Stockpile Programs

• 12.2 AV7909 (Anthrax Vaccine Adsorbed + CPG7909 Adjuvant by Emergent BioSolutions): Reduced 3-Dose Post-Exposure Prophylaxis Schedule; BARDA Advanced Development Contract; FDA Animal Rule Efficacy Data and Pathway to EUA/BLA

• 12.3 Recombinant Protective Antigen (rPA) Vaccines: GC Biopharma Recombinant rPA Anthrax Vaccine; NIAID rPA102 Program; Advantages over Cell-Free PA Vaccines in Defined Composition, Scalability, and Thermostability

• 12.4 Anthrax Monoclonal Antibody Countermeasures: Obiltoxaximab (Anthim/Scorpius BioManufacturing–Elusys Therapeutics), Raxibacumab (ABthrax/Human Genome Sciences/GSK), and Anthrax Antitoxin (AIG/Cangene) for Post-Exposure Prophylaxis and Treatment

• 12.5 Next-Generation Anthrax Vaccine Platforms: Thermostable Spray-Dried Formulations, IL-33 Adjuvant Systems, Nanoparticle-Based Antigen Delivery, DNA Vaccines, Viral Vector (Adenovirus) Platforms, and mRNA-Based Anthrax Vaccine Research

• 12.6 Veterinary Anthrax Vaccine Innovation: Improved Sterne Strain Adjuvanted Formulations, Thermostable Lyophilized Veterinary Vaccines for LMIC Field Use, and Combination Anthrax-Clostridium Multivalent Livestock Vaccines

13. Global Anthrax Vaccine Market Size and Forecast (2026–2033)

• 13.1 Historical Market Size and Trends

• 13.2 Base Year Market Size (2025)

• 13.3 Current Year Market Size (2026) 

• 13.4 Market Size Forecast (USD Billion, 2026–2033)

• 13.5 Year-on-Year Growth Analysis

• 13.6 CAGR Analysis (2026–2033) 

• 13.7 Absolute Dollar Opportunity Assessment

14. Market Segmentation Analysis

14.1 By Vaccine Type

• 14.1.1 Cell-Free Protective Antigen (PA) Vaccines (Dominant – 63.40% Share in 2025)​

  • Anthrax Vaccine Adsorbed (AVA) – BioThrax (Emergent BioSolutions): FDA-Licensed; U.S. Military and SNS Standard; 5-Dose Priming + Annual Boosters; BARDA Procurement Contract

  • Anthrax Vaccine Precipitated (AVP) – CHPA (Porton Biopharma/UK MHRA Licensed): UK Military and High-Risk Group Vaccination; 4-Dose Priming + Annual Boosters

  • Cell-Free PA Vaccine Post-Exposure Prophylaxis (PEP) Use with 60-Day Antibiotic Co-Administration (ACAM2AX Program)

  • AV7909 (AVA+CPG7909): Next-Generation Adjuvanted AVA for 3-Dose PEP Schedule; BARDA Advanced Development

• 14.1.2 Live Attenuated Vaccines

  • Sterne Strain (34F2) Live Attenuated Vaccine: Standard Veterinary Anthrax Vaccine for Livestock; USDA-Licensed; Used in Africa, Asia, Latin America, and Endemic Regions

  • Veterinary Multi-Dose Formulations: Colorado Serum Company, JOVAC, Indian Immunologicals, CAVAC, Biogénesis-Bagó Sterne Strain Vaccine Products

  • Russian Live Spore Vaccine (STI Strain): Used in Former Soviet States and Eastern Europe for Livestock Vaccination Programs

• 14.1.3 Recombinant Subunit Vaccines (Fastest-Growing Vaccine Type)

  • rPA102 (NIAID/Emergent BioSolutions): Phase I/II Recombinant PA Anthrax Vaccine with Well-Defined Composition and Improved Safety Profile

  • GC Biopharma Recombinant rPA Anthrax Vaccine: South Korean Recombinant Platform Entry; Asia-Pacific Market Focus

  • iBio AI-Guided Recombinant Anthrax Antibody Design: Plant-Made Recombinant Anthrax Antigen Production Platform

• 14.1.4 Next-Generation Platform Vaccines

  • Thermostable Spray-Dried and Lyophilized Anthrax Vaccine Formulations for Reduced Cold Chain Dependency

  • Nanoparticle-Based Anthrax PA Antigen Delivery Platforms: Self-Assembling Protein Nanoparticles (SAPNs) for Enhanced Immunogenicity

  • Viral Vector (Adenovirus)-Based Anthrax PA Vaccine: Intranasal Mucosal Immunity Platform for Inhalation Anthrax Protection

  • mRNA-Based Anthrax Vaccine Research Programs: Proof-of-Concept Studies Post-COVID-19 mRNA Technology Validation

14.2 By Vaccine Platform

• 14.2.1 Cell-Free PA Platform (Dominant)

  • Alhydrogel-Adjuvanted PA Adsorbed Vaccine (AVA/BioThrax)

  • Aluminum Hydroxide-Precipitated PA Vaccine (AVP/CHPA)

  • CPG7909 TLR9 Agonist-Adjuvanted PA Platform (AV7909)

• 14.2.2 Live Attenuated Bacillus anthracis Sterne Strain Platform

  • 34F2 Sterne Strain (Porcine Gelatin Stabilized): Standard Global Veterinary Anthrax Vaccine

  • STI Strain (Russian Federation): Human Use in Former Soviet States (Controversial – Limited Western Use)

• 14.2.3 Recombinant Protective Antigen (rPA) Platform

  • E. coli-Expressed rPA with Standard Alhydrogel Adjuvant (rPA102)

  • Plant-Based and Yeast-Based rPA Expression Systems for Scale Manufacturing

• 14.2.4 Nanoparticle-Based Platform

  • Self-Assembling Protein Nanoparticle (SAPN) Anthrax PA Antigen Displays for Potent Multi-Epitope Immune Response

• 14.2.5 Viral Vector Platform

  • Adenovirus-Based PA Vaccine for Mucosal Intranasal Delivery Targeting Inhalation Anthrax

• 14.2.6 DNA Vaccine Platform

  • Plasmid DNA-Based Anthrax PA Vaccines in Preclinical Research Phase

• 14.2.7 mRNA Platform

  • mRNA-Encoded PA Antigen Vaccine Research Programs; Proof-of-Concept Studies Supported by COVID-19 mRNA Validation

14.3 By Application

• 14.3.1 Animal Use (Dominant Application – Largest Market Share in 2025)

  • Livestock Vaccination (Cattle, Sheep, Goats, Horses, Pigs): Annual Sterne Strain Vaccination in Endemic Regions (Sub-Saharan Africa, Central Asia, South/Southeast Asia, Latin America)

  • Wildlife Anthrax Control: Anthrax Vaccination of Endangered Wildlife (African Elephant, Hippopotamus Programs in National Parks)

  • WOAH/OIE-Supported National Livestock Anthrax Control Programs in High-Burden Countries

  • Veterinary Emergency Response Vaccination Campaigns During Anthrax Outbreak Events

• 14.3.2 Human Use (Fastest-Growing Application – Driven by Biodefense Investment)

  • Military Pre-Exposure Prophylaxis: U.S. DoD Mandatory BioThrax Vaccination for Deployed Military Personnel; NATO Allied Force Anthrax Immunization Programs

  • Government Biodefense Stockpile (SNS): Strategic National Stockpile BioThrax/AV7909 Procurement for Emergency Post-Exposure Use in Bioterrorism Attack Response

  • Occupational Risk Group Vaccination: Laboratory Workers Handling B. anthracis, Veterinarians, Agricultural Workers in Endemic Regions, Wool/Textile Industry Workers

  • Post-Exposure Prophylaxis (PEP): Anthrax Vaccine + 60-Day Ciprofloxacin/Doxycycline for Suspected Inhalation Anthrax Exposure

14.4 By Route of Administration

• 14.4.1 Subcutaneous/Intramuscular Injection (Dominant – Standard Licensed Route)

  • BioThrax Subcutaneous 5-Dose Priming Schedule; FDA-Approved IM Route for Pre-Exposure Use

  • Sterne Strain Subcutaneous Veterinary Administration

  • Recombinant rPA Vaccines Intramuscular Administration

• 14.4.2 Intradermal Administration

  • Dose-Sparing Intradermal AVA Immunization Research for Mass Civilian Vaccination Scenarios

• 14.4.3 Intranasal/Mucosal Administration (Pipeline)

  • Adenovirus-Vectored Intranasal Anthrax Vaccine for Mucosal IgA-Mediated Inhalation Anthrax Protection

  • AltImmune/Altimmune Intranasal Anthrax Vaccine (AG-702) Clinical Development Program

14.5 By End User

• 14.5.1 Military and Defense Agencies (Dominant Human Use End User)

  • U.S. Department of Defense (DoD) Mandatory Anthrax Immunization Program (MAIP)

  • NATO Allied Military Medical Commands and European Defense Force Anthrax Vaccination Programs

  • U.S. National Guard, Reserve Forces, and Civilian First Responders with Bioterrorism Risk

• 14.5.2 Government Biodefense Stockpile Programs

  • U.S. Strategic National Stockpile (SNS) BioThrax and AV7909 BARDA Procurement

  • UK Government CHPA/AVP Stockpile for Emergency Civilian Population Post-Exposure Prophylaxis

  • Allied Nation Biodefense Stockpile Programs (France, Germany, Israel, Australia)

• 14.5.3 Veterinary Hospitals and Clinics (Dominant Animal Use End User)

  • Large Animal Veterinary Practices in Anthrax-Endemic Agricultural Regions

  • State and Federal Veterinary Authorities Administering Mass Livestock Vaccination Campaigns

  • Wildlife Veterinary Services for Anthrax Control in Conservation Areas

• 14.5.4 Hospitals and Clinics

  • Occupational Health Clinics for Laboratory Worker and Agricultural Worker Pre-Exposure Vaccination

  • Emergency Department and Infectious Disease Units for Post-Exposure Prophylaxis Management

• 14.5.5 Research and Academic Institutes

  • NIAID, USAMRIID, DSTL, Porton Down, and Academic Research Centers for Anthrax Vaccine Development and Animal Model Challenge Studies

  • BSL-3 Research Laboratories for New Anthrax Vaccine Platform Development

• 14.5.6 Agricultural and Livestock Organizations

  • National Livestock Disease Control Authorities in Africa, Asia, and Latin America

  • Private Farm Operations and Livestock Cooperatives in Anthrax-Endemic Regions

14.6 By Distribution Channel

• 14.6.1 Government Biodefense Procurement / BARDA / SNS (Dominant – Largest Channel for Human Anthrax Vaccines)

  • BARDA Other Transaction Authority (OTA) and Fixed-Price Contracts for BioThrax and AV7909 Procurement

  • U.S. SNS Bulk Stockpile Management by ASPR/HHS

  • Allied Nation Government-to-Government Anthrax Vaccine Supply Agreements

• 14.6.2 Veterinary Distributors

  • National Veterinary Product Distributors for Sterne Strain Vaccine Distribution in Africa, Asia, and Latin America

  • WOAH/FAO-Supported Veterinary Anthrax Vaccine Procurement Channels for LMICs

• 14.6.3 Hospital Pharmacies

  • Specialty Pharmacy Dispensing of BioThrax for Occupational Vaccination Programs

  • Hospital-Based Post-Exposure Prophylaxis Anthrax Vaccine + Antibiotic Administration

• 14.6.4 Specialty Distributors

  • Specialty Biodefense Countermeasure Distributors Supplying Occupational Health Clinics, Research Facilities, and National Laboratories

• 14.6.5 Online Medical Supply

  • E-Commerce Medical Supply Channels for Veterinary Anthrax Vaccine Kit Procurement by Licensed Agricultural Practitioners

14.7 By Region

• 14.7.1 North America (Dominant – 44.70% Share in 2025)

• 14.7.2 Europe

• 14.7.3 Asia Pacific (Fastest-Growing Region)

• 14.7.4 Latin America / South America

• 14.7.5 Middle East and Africa

15. Regional Market Analysis

15.1 North America

• 15.1.1 Market Overview and Key Trends (Dominant – 44.70% Share in 2025; BARDA/SNS BioThrax Procurement Leader; U.S. DoD Mandatory Anthrax Immunization Program; AV7909 Advanced Development)

• 15.1.2 Market Size and Forecast (North America Anthrax Vaccine Market – USD 4.7 Billion in 2023)​

• 15.1.3 Market Share by Segment

• 15.1.4 Country-Level Analysis

  • United States (World's Largest Anthrax Vaccine Market; BARDA BioThrax SNS Contract; DoD MAIP; AV7909 BARDA Development Contract; USAMRIID R&D Programs)

  • Canada (Public Health Agency of Canada Biodefense Programs; National Emergency Stockpile System Anthrax Countermeasures)

  • Mexico

• 15.1.5 Market Attractiveness Analysis

15.2 Europe

• 15.2.1 Market Overview and Key Trends (UK CHPA/AVP Stockpile; Porton Biopharma as UK Licensed Producer; NATO Biodefense Policy; EU Civil Protection Anthrax Countermeasure Programs)

• 15.2.2 Market Size and Forecast

• 15.2.3 Market Share by Segment

• 15.2.4 Country-Level Analysis

  • United Kingdom (DSTL Porton Down; CHPA AVP Vaccine; UK MoD Military Vaccination Programs; UKHSA Bioterrorism Preparedness)

  • Germany (Bundeswehr Anthrax Vaccination; Robert Koch Institute Biodefense Programs)

  • France (DGA Biodefense Research; ANSM Vaccine Authorization)

  • Russia (Anthrax Endemic in Siberia and Central Russia; FGBU and Gamaleya Institute Live Attenuated STI Strain Programs)

  • Rest of Europe

• 15.2.5 Market Attractiveness Analysis

15.3 Asia Pacific

• 15.3.1 Market Overview and Key Trends (Fastest-Growing Region; Large Livestock Populations; Anthrax Endemic in India, China, Central Asia; Government Veterinary Vaccination Investment Expansion; GC Biopharma Recombinant Vaccine Entry)

• 15.3.2 Market Size and Forecast

• 15.3.3 Market Share by Segment

• 15.3.4 Country-Level Analysis

  • India (Indian Immunologicals Sterne Strain Veterinary Vaccine; DCGI Regulatory Framework; High Livestock Anthrax Risk in Andhra Pradesh and Karnataka)

  • China (CNBG Anthrax Vaccine Programs; NMPA Regulatory Pathway; High Livestock Population)

  • South Korea (GC Biopharma Recombinant rPA Anthrax Vaccine Development; MFDS Regulatory Pathway; Military Biodefense Program)

  • Japan (PMDA Biodefense Vaccine Regulatory Framework; JGSDF Military Biodefense Programs)

  • Australia (TGA Anthrax Countermeasure Authorization; DSTO Biodefense Research)

  • Rest of Asia Pacific

• 15.3.5 Market Attractiveness Analysis

15.4 Latin America / South America

• 15.4.1 Market Overview and Key Trends (Anthrax Endemic in Bolivia, Brazil, Peru, Venezuela; Large Cattle Population; PAHO/PANAFTOSA Veterinary Anthrax Control Programs; Biogénesis-Bagó and VECOL Sterne Strain Production)

• 15.4.2 Market Size and Forecast (Latin America – 6% Global Market Share in 2025)​

• 15.4.3 Market Share by Segment

• 15.4.4 Country-Level Analysis

  • Brazil (MAPA LANAGRO Veterinary Vaccine Regulation; Anthrax Risk in Cattle-Producing States; VACINAR Program)

  • Colombia (VECOL S.A. Anthrax Vaccine Production; AGROSAVIA Agricultural Research)

  • Argentina (SENASA Veterinary Vaccine Regulation; Biogénesis-Bagó Sterne Strain Production)

  • Rest of South America

• 15.4.5 Market Attractiveness Analysis

15.5 Middle East and Africa

• 15.5.1 Market Overview and Key Trends (Sub-Saharan Africa High Anthrax Burden in Livestock and Wildlife; Botswana, Zimbabwe, Uganda, Kenya Anthrax Hotspots; Botswana Vaccine Institute Sterne Strain Production; WOAH-Supported Control Programs; MEA 4% Global Market Share in 2025)

• 15.5.2 Market Size and Forecast

• 15.5.3 Market Share by Segment

• 15.5.4 Country-Level Analysis

  • Botswana (Botswana Vaccine Institute – Major African Sterne Strain Producer; High Wildlife Anthrax Risk in Chobe National Park)

  • Zimbabwe (High Livestock Anthrax Risk; DVS National Vaccination Programs)

  • Kenya (Anthrax in Tsavo National Park Wildlife and Northern Province Livestock; KVB Programs)

  • South Africa (ARC-OVI Anthrax Research; Kruger National Park Wildlife Surveillance)

  • Rest of Middle East and Africa

• 15.5.5 Market Attractiveness Analysis

16. Competitive Landscape

• 16.1 Market Concentration and Competitive Intensity

• 16.2 Market Share Analysis of Key Players (Emergent BioSolutions – Dominant Human Vaccine Market Leader; Porton Biopharma; GC Biopharma; Indian Immunologicals; Colorado Serum Company; Zoetis; Merck Animal Health; Biogénesis-Bagó; Botswana Vaccine Institute)

• 16.3 Market Ranking and Positioning Analysis

• 16.4 Competitive Strategies and Benchmarking

• 16.5 Recent Developments and Strategic Moves

  • 16.5.1 Emergent BioSolutions BARDA AV7909 Advanced Development Contract Progress and BLA Submission Pathway for Post-Exposure Prophylaxis Indication

  • 16.5.2 GC Biopharma Recombinant rPA Anthrax Vaccine Entry: South Korea Military Biodefense Program and Asia-Pacific Market Expansion

  • 16.5.3 Scorpius BioManufacturing–Obiltoxaximab (Anthim) CDMO Manufacturing Partnership Diversifying Anthrax mAb Supply Chain

  • 16.5.4 iBio AI-Guided Anthrax Antibody Design: Next-Generation Recombinant Anthrax Countermeasure Development Using Artificial Intelligence

  • 16.5.5 Patent Filings for IL-33 Adjuvant Systems, Thermostable Formulations, and Spray-Drying Techniques: Next-Generation Shelf-Stable Anthrax Vaccine Innovation Pipeline

• 16.6 Competitive Dashboard and Company Evaluation Matrix

17. Company Profiles

The final report includes a complete list of companies

17.1 Emergent BioSolutions Inc.

• Company Overview

• Financial Performance

• Product Portfolio

• Strategic Initiatives

• SWOT Analysis

17.2 Porton Biopharma Limited

17.3 GC Biopharma Corporation

17.4 Indian Immunologicals Limited

17.5 Colorado Serum Company

17.6 Zoetis, Inc.

17.7 Merck Animal Health (Merck & Co., Inc.)

17.8 Biogénesis-Bagó S.A.

17.9 VECOL S.A.

17.10 Botswana Vaccine Institute (BVI)

17.11 Bayer Animal Health (Elanco Animal Health)

17.12 JOVAC (Jordan Bio Industries Center)

17.13 Ceva Santé Animale

17.14 Valneva SE

17.15 Altimmune, Inc.

18. Technology and Innovation Trends

• 18.1 AV7909 (AVA+CPG7909 Adjuvant): Transforming Anthrax Post-Exposure Prophylaxis with Reduced 3-Dose Schedule, Enhanced Immunogenicity, and BARDA-Supported FDA BLA/EUA Pathway

• 18.2 Recombinant Protective Antigen (rPA) Vaccine Platforms: GC Biopharma, NIAID rPA102, and Next-Generation E. coli and Yeast-Expressed rPA Vaccines Offering Defined Composition, Scalability, and Thermostability Advantages

• 18.3 Thermostable and Spray-Dried Anthrax Vaccine Formulations: Eliminating Cold Chain Dependency for Global South Military and Veterinary Deployment; IL-33 Adjuvant System Development

• 18.4 AI-Guided Anthrax Countermeasure Design: iBio and Synthetic Biology Approaches to Accelerated Novel Anthrax Antibody and Antigen Candidate Discovery

• 18.5 mRNA and Viral Vector Anthrax Vaccine Research: Post-COVID-19 mRNA Platform Application to Anthrax PA Antigen Encoding and Adenovirus-Vectored Mucosal Vaccine Development for Inhalation Anthrax Protection

19. Regulatory and Compliance Landscape

• 19.1 Overview of Global Regulatory Framework for Human and Veterinary Anthrax Vaccines (FDA CBER, USDA APHIS, EMA, MHRA, PMDA, CDSCO)

• 19.2 FDA Animal Rule (21 CFR 314.600 and 601.90) for Anthrax Vaccine Efficacy: Non-Human Primate and Rabbit Inhalation Anthrax Challenge Study Requirements and Immunological Bridging Studies for Human Approval

• 19.3 BARDA Project BioShield and Other Transaction Authority (OTA) Contracts: Procurement Mechanism for BioThrax, AV7909, and Anthrax mAb SNS Stockpiling

• 19.4 USDA Center for Veterinary Biologics (CVB) Licensing for Animal Anthrax Vaccines: Sterne Strain Potency Standards, Label Requirements, and Import/Export Restrictions

• 19.5 WOAH/OIE International Standards for Anthrax Diagnosis and Vaccination: Terrestrial Animal Health Code Chapter 8.1 and Manual of Diagnostic Tests and Vaccines for Terrestrial Animals – Anthrax Chapter

• 19.6 International Export Controls and Select Agent Regulations for B. anthracis-Derived Biological Materials: CDC/USDA Select Agent Program, Australia Group Export Controls, and Biological Weapons Convention (BWC) Compliance

20. Patent and Intellectual Property Analysis

• 20.1 Key Patents in Recombinant PA Antigen Production, CPG7909 Adjuvant Systems, IL-33 Adjuvant Formulations, Thermostable/Spray-Dried Anthrax Vaccine Formulations, Anthrax mAb Sequences (Obiltoxaximab, Raxibacumab), and Nanoparticle Delivery Systems

• 20.2 Patent Landscape by Vaccine Type and Platform Technology

• 20.3 Regional Patent Filing Trends (U.S., EU, South Korea, India, China)

• 20.4 Patent Expiry and Generic/Biosimilar Anthrax Vaccine Entry Considerations

• 20.5 Emerging Patent Activity: mRNA Anthrax Vaccine Sequences, AI-Generated Anthrax Antibody Designs, Thermostable Formulation Technology, and Anthrax-Clostridium Combination Veterinary Vaccine Patents

21. ESG and Sustainability Analysis

• 21.1 Environmental Sustainability: BSL-3 Biocontainment Compliance in Anthrax Vaccine Manufacturing, B. anthracis Spore Waste Disposal Standards, Cold Chain Carbon Footprint Reduction via Thermostable Formulations, and Sustainable CDMO Manufacturing Practices

• 21.2 Social Responsibility: One Health Approach to Anthrax Control – Protecting Livelihoods of Livestock-Dependent Communities in Sub-Saharan Africa and Asia, Expanding Access to Veterinary Anthrax Vaccines in LMICs, and Global Biodefense Equity

• 21.3 Governance and Ethical Standards: Transparent BARDA Procurement Contracting, Responsible Biodefense Research Oversight Under Select Agent Regulations, Ethical Animal Challenge Study Conduct Under 3Rs Principles (Replace, Reduce, Refine), and Responsible Dual-Use Research of Concern (DURC) Framework

• 21.4 Corporate ESG Initiatives by Emergent BioSolutions, Zoetis, Merck Animal Health, and Other Key Anthrax Vaccine Market Players

22. Epidemiology and Clinical Demand Analysis

• 22.1 Global Anthrax Epidemiology: Natural Disease Incidence in Livestock and Wildlife; Geographic Distribution of Anthrax-Endemic Zones (Sub-Saharan Africa, Central Asia, South Asia, Latin America, Eastern Europe)

• 22.2 Human Anthrax Cases: Occupational, Agricultural, and Industrial Anthrax (Cutaneous, Inhalation, Gastrointestinal); Bioterrorism-Associated Anthrax Risk Assessment

• 22.3 Veterinary Anthrax Burden: Annual Livestock Losses, High-Risk Species (Cattle, Goats, Sheep, Horses), Outbreak Hotspot Countries, and Economic Cost of Anthrax on Agricultural Sectors

• 22.4 Climate Change and Anthrax Risk: Permafrost Thaw (Siberia 2016), Flood-Driven Spore Dispersal, and Environmental Monitoring for Anthrax Carcass Sites

• 22.5 Bioterrorism Risk Assessment: Intelligence-Driven Biodefense Procurement Demand and Scenario Planning for Mass Casualty Inhalation Anthrax Attack Response

23. Anthrax Vaccine Market Trends and Strategies

• 23.1 Current Market Trends

  • 23.1.1 Cell-Free PA Vaccines Maintaining Market Dominance (~63.40% Share in 2025); Recombinant Subunit Vaccines Fastest-Growing Type

  • 23.1.2 Animal Use Dominating Application Segment; Human Use Fastest-Growing Driven by Biodefense Investment

  • 23.1.3 Military and Government End Users Dominating Human Anthrax Vaccine Procurement; Veterinary Hospitals Dominating Animal Use Segment

  • 23.1.4 Government Biodefense Procurement (BARDA/SNS) Dominating Distribution Channel

  • 23.1.5 North America Maintaining 44.70% Regional Dominance; Asia-Pacific Fastest-Growing Region

• 23.2 BARDA Contract Management and SNS Stockpile Replenishment Strategy for Human Anthrax Vaccine Manufacturers

• 23.3 Supplier Diversification Strategy: BARDA and National Biodefense Policy Shift Toward Multiple Licensed Anthrax Vaccine Sources Reducing Single-Supplier Dependency

• 23.4 Veterinary Market Expansion Strategy: WOAH Prequalification, GFATM/FAO Procurement Programs, and National Veterinary Authority Partnership in Endemic Countries

• 23.5 Next-Generation Platform Differentiation: Thermostable Formulation, Reduced Dosing Schedule, and Recombinant PA Advantages as Key Commercial Differentiation Strategies

24. Strategic Recommendations

• 24.1 Recommendations for Emergent BioSolutions on AV7909 BLA/EUA Submission Strategy, BARDA Contract Renewal, SNS Stockpile Expansion, and International Military Market Diversification

• 24.2 Recommendations for Recombinant Anthrax Vaccine Developers (GC Biopharma, NIAID rPA102) on FDA Animal Rule Clinical Development Strategy, Thermostable Formulation Prioritization, and Asia-Pacific Biodefense Market Entry

• 24.3 Recommendations for Veterinary Anthrax Vaccine Manufacturers (Indian Immunologicals, Colorado Serum, Biogénesis-Bagó, Botswana Vaccine Institute) on WOAH Prequalification, FAO Supply Partnership, and Regional Livestock Market Expansion

• 24.4 Recommendations for Animal Health Giants (Zoetis, Merck Animal Health, Bayer/Elanco) on Anthrax-Clostridium Combination Vaccine Development, Thermostable Field Formulation Launch, and Sub-Saharan Africa Market Investment

• 24.5 Regional Expansion Strategies: Asia-Pacific Veterinary Vaccination Program Partnership, Sub-Saharan Africa WOAH/FAO Collaboration, and Latin America PAHO/PANAFTOSA Anthrax Control Program Entry

• 24.6 Regulatory Strategy Roadmap: FDA Animal Rule Compliance for Human Vaccine BLA, USDA CVB Veterinary Biologics Licensing, EMA Marketing Authorization, and BARDA OTA Contract Optimization

25. Key Mergers and Acquisitions

• 25.1 Overview of M&A and Strategic Partnership Activity in the Anthrax Vaccine Market

• 25.2 Major Transactions and Strategic Rationale

  • Emergent BioSolutions Acquisition of Cangene Corporation (2013): Adding Anthrax Antitoxin (AIG) and rPA102 Pipeline Assets

  • Boehringer Ingelheim Acquisition of Merial (2017): Expanding Animal Health and Veterinary Anthrax Vaccine Portfolio

  • Elanco Animal Health Acquisition of Bayer Animal Health (2020): Strengthening Veterinary Vaccine Portfolio Including Anthrax-Endemic Market Products

  • Scorpius BioManufacturing CDMO Partnership with Elusys Therapeutics for Obiltoxaximab (Anthim) Manufacturing

  • GC Biopharma Recombinant Anthrax Vaccine Development Agreement with South Korean Government Defense Acquisition Program Administration (DAPA)

• 25.3 Impact on Market Dynamics, Product Portfolio, Manufacturing Capacity, and Competitive Positioning

26. High-Potential Segments and Growth Strategies

• 26.1 High-Growth Segments (Recombinant Subunit Vaccines, Human Use – Biodefense Application, Intranasal/Mucosal Pipeline Vaccines, Asia-Pacific Region, Government Biodefense Procurement Channel, mRNA and Viral Vector Platform Innovation)

• 26.2 Emerging Geographies with Strongest Market Potential (India, China, South Korea, Kazakhstan, Uganda, Brazil, Kenya)

• 26.3 Growth Strategies

  • 26.3.1 Market Trend-Based Strategies (AV7909 Post-Exposure Prophylaxis Commercialization, Thermostable Formulation Launch, Recombinant rPA Platform Expansion, One Health Dual-Use Market Development)

  • 26.3.2 Competitor Benchmarking and Differentiation Strategies (Reduced Dosing Schedule as Competitive Advantage, BARDA Contract Diversification, Thermostable Veterinary Vaccine Field Deployment, AI-Guided Next-Generation Antigen Design)

27. Future Market Outlook and Trends (2026–2033)

• 27.1 AV7909 Receiving FDA BLA/EUA Approval by 2027–2028: Replacing BioThrax (AVA) as the Standard U.S. SNS Post-Exposure Prophylaxis Vaccine and Driving Next-Generation BARDA Contract Revenue

• 27.2 Recombinant rPA Vaccines Gaining Global Regulatory Approvals by 2028–2030: GC Biopharma, NIAID rPA102, and Allied Nation Recombinant Platforms Creating Competitive Market for BioThrax Replacement

• 27.3 Thermostable Lyophilized Anthrax Vaccines Enabling Cold-Chain-Independent Mass Livestock Vaccination in Africa and Asia by 2028–2030: WOAH/FAO-Supported Deployment in Sub-Saharan Africa and South Asia

• 27.4 Asia-Pacific Surpassing Europe as Second-Largest Anthrax Vaccine Market by 2030–2033: India and China Veterinary Vaccination Scale-Up, South Korea Recombinant Vaccine Export, and ASEAN Biodefense Investment Growth

28. Conclusion

• 28.1 Summary of Key Findings

• 28.2 Market Outlook Summary (2026–2033)

• 28.3 Future Growth Drivers and Opportunities

• 28.4 Final Insights and Strategic Perspectives

29. Appendix

• 29.1 List of Abbreviations and Acronyms

• 29.2 Glossary of Technical Terms (AVA, AVP, PA, rPA, AV7909, CPG7909, SNS, BARDA, PHEMCE, DoD, MAIP, WOAH/OIE, USDA APHIS, CVB, FDA CBER, BLA, EUA, DURC, BSL-3, USAMRIID, DSTL, OTA, 3Rs, CDMO, mAb, IL-33, SAPN, BWC, Select Agent, DAPA, LANAGRO, SENASA, MAPA, PANAFTOSA, PAHO, NHP, Animal Rule, etc.)

• 29.3 Research Instruments and Questionnaires 

• 29.4 List of Figures and Tables

• 29.5 List of Primary and Secondary Data Sources

• 29.6 Additional Resources and References

30. Disclaimer